Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Routy

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Oncoimmunology|July 4, 2025
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancerLéa Montégut, Adrien Rousseau, Cinzia Ungolo, et al.
JTO Clinical and Research Reports|December 21, 2023
Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Scientific Reports|July 8, 2023
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional studySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Physiologic colonic uptake of <sup>18</sup>F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitorsLena Cvetkovic, Claudine Régis, Corentin Richard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapyMarion Tonneau, Corentin Richard, Bertrand Routy, et al.
Oncoimmunology|February 16, 2017
The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantationBertrand Routy, Caroline Letendre, David Enot, et al.
Cancer Treatment and Research Communications|October 13, 2023
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapyFrancis Proulx-Rocray, Bertrand Routy, Rami Nassabein, et al.
Current Oncology (Toronto, Ont.)|January 27, 2021
Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLCCamille Gauvin, Vimal Krishnan, Imane Kaci, et al.
Egastroenterology|February 13, 2025
Causal role of the gut microbiome in certain human diseases: a narrative reviewConnor Prosty, Khaled Katergi, Jesse Papenburg, et al.
Immunity|June 23, 2016
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic FactorsJonathan M Pitt, Marie Vétizou, Romain Daillère, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Oncoimmunology|July 4, 2025
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancerLéa Montégut, Adrien Rousseau, Cinzia Ungolo, et al.
JTO Clinical and Research Reports|December 21, 2023
Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Scientific Reports|July 8, 2023
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional studySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Physiologic colonic uptake of <sup>18</sup>F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitorsLena Cvetkovic, Claudine Régis, Corentin Richard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapyMarion Tonneau, Corentin Richard, Bertrand Routy, et al.
Oncoimmunology|February 16, 2017
The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantationBertrand Routy, Caroline Letendre, David Enot, et al.
Cancer Treatment and Research Communications|October 13, 2023
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapyFrancis Proulx-Rocray, Bertrand Routy, Rami Nassabein, et al.
Current Oncology (Toronto, Ont.)|January 27, 2021
Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLCCamille Gauvin, Vimal Krishnan, Imane Kaci, et al.
Egastroenterology|February 13, 2025
Causal role of the gut microbiome in certain human diseases: a narrative reviewConnor Prosty, Khaled Katergi, Jesse Papenburg, et al.
Immunity|June 23, 2016
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic FactorsJonathan M Pitt, Marie Vétizou, Romain Daillère, et al.
Pageof 13